Alnylam Pharmaceuticals, Inc. which can be found using ticker (ALNY) have now 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 415 and 136 with the average target price sitting at $250.54. Now with the previous closing price of $205.36 this now indicates there is a potential upside of 22.0%. The day 50 moving average is $198.56 and the 200 moving average now moves to $210.16. The total market capitalization for the company now stands at 26.27B. The stock price is currently at: 206.2 USD
The potential market cap would be $32,050,865,462 based on the market consensus.
USD
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 9.33 and a -14.43% return on assets.
